These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 6205521)

  • 21. Mediation of trypsin inhibitor-induced pancreatic hypersecretion by secretin and cholecystokinin in rats.
    Watanabe S; Takeuchi T; Chey WY
    Gastroenterology; 1992 Feb; 102(2):621-8. PubMed ID: 1732130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the serine protease inhibitor gabexate mesilate on purified pancreatic phospholipase A2.
    Hesse B; Lankisch PG; Kunze H
    Pharmacol Res Commun; 1984 Jul; 16(7):637-45. PubMed ID: 6433363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the serine protease inhibitors FOY and FOY 305 on phospholipase A1 (EC 3.1.1.32) activity in rat - liver lysosomes.
    Kunze H; Bohn E
    Pharmacol Res Commun; 1983 May; 15(5):451-9. PubMed ID: 6412250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of synthetic trypsin inhibitor on plasma immunoreactive cholecystokinin in rats.
    Kanayama S; Himeno S; Yamasaki Y; Shinomura Y; Kitani T; Tarui S
    Gastroenterol Jpn; 1987 Apr; 22(2):211-7. PubMed ID: 3596156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of synthetic protease inhibitor camostate on pancreatic exocrine function in rats.
    Otsuki M; Ohki A; Okabayashi Y; Suehiro I; Baba S
    Pancreas; 1987; 2(2):164-9. PubMed ID: 3628222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of trypsin inhibitor (camostate) on pancreas and CCK release in young and old female rats.
    Miyasaka K; Nakamura R; Kitani K
    J Gerontol; 1989 Jul; 44(4):M136-40. PubMed ID: 2738309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of a small molecular weight proteinase inhibitor, gabexate mesilate (FOY), on insulin receptor function in vitro.
    Göke R; Göke B; Steinfelder HJ; Arnold R
    Int J Pancreatol; 1988 Mar; 3(2-3):135-42. PubMed ID: 3129526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stimulation of the growth of azaserine-induced nodules in the rat pancreas by dietary camostate (FOY-305).
    Lhoste EF; Roebuck BD; Longnecker DS
    Carcinogenesis; 1988 Jun; 9(6):901-6. PubMed ID: 3259478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreatic regeneration after partial pancreatectomy.
    Parekh D; Townsend CM; Rajaraman S; Ishizuka J; Thompson JC
    Am J Surg; 1991 Jan; 161(1):84-8; discussion 88-9. PubMed ID: 1702941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Okadaic acid disrupts Golgi structure and impairs enzyme synthesis and secretion in the rat pancreas.
    Waschulewski IH; Kruse ML; Agricola B; Kern HF; Schmidt WE
    Am J Physiol; 1996 Jun; 270(6 Pt 1):G939-47. PubMed ID: 8764200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of gabexate mesilate (FOY) on amylase and phospholipase A2 in human serum and pancreatic juice.
    Caronna R; Diana L; Nofroni I; Sibio S; Catinelli S; Sammartino P; Chirletti P
    Dig Dis Sci; 2005 May; 50(5):868-73. PubMed ID: 15906759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The effect of oral synthetic protease inhibitor (FOY 305) on endocrine pancreas and carbohydrate and lipid metabolism in normal and streptozotocin-induced diabetic rats].
    Eto M; Watanabe K; Kagaya T; Sakai Y; Yoshida S; Oyama K; Futaki G; Saito T; Takebe T; Ishii K
    Nihon Naibunpi Gakkai Zasshi; 1984 May; 60(5):684-95. PubMed ID: 6386547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stimulation of pancreatic secretory process in the rat by low-molecular weight proteinase inhibitor. III. Changes in DNA synthesis and mitotic activity.
    Elsässer HP; Puplat D; Adler G; Kern HF
    Cell Tissue Res; 1990 Oct; 262(1):143-8. PubMed ID: 2257606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brefeldin A induced dose-dependent changes to Golgi structure and function in the rat exocrine pancreas.
    Kömhoff M; Hollinshead M; Tooze J; Kern HF
    Eur J Cell Biol; 1994 Apr; 63(2):192-207. PubMed ID: 8082645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro inhibition of phospholipase A2 by gabexate mesilate, camostate, and aprotinine.
    Freise J; Wittenberg H; Magerstedt P
    Klin Wochenschr; 1989 Feb; 67(3):149-52. PubMed ID: 2467043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased CCK-response to proteinase inhibitor feeding after induction of pancreatic hypertrophy in rats.
    Göke B; Fenchel K; Knobloch S; Arnold R; Adler G
    Pancreas; 1988; 3(5):576-9. PubMed ID: 3186685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitory effect of gabexate mesilate on pancreatic phospholipase A2-mediated hydrolysis of ghost membranes.
    Nishijima J; Okamoto M; Nakaguchi K; Ogawa M; Yamano T; Mori T
    Gen Pharmacol; 1985; 16(3):177-82. PubMed ID: 3926598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of proteinase inhibitor camostat on exocrine pancreas in fed and fasted rats.
    Otsuki M; Tani S; Fujii M; Nakamura T; Okabayashi Y; Koide M
    Am J Physiol; 1993 Oct; 265(4 Pt 2):R896-901. PubMed ID: 7694489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevation of resting fluid secretion precedes trophic responses in the rat pancreas following a single oral administration of Camostat.
    Terasawa K; Kanno T
    Int J Pancreatol; 1991 Apr; 8(3):263-74. PubMed ID: 2051064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of atropine and a cholecystokinin receptor antagonist on pancreatic secretion.
    Adler G; Reinshagen M; Koop I; Göke B; Schafmayer A; Rovati LC; Arnold R
    Gastroenterology; 1989 Apr; 96(4):1158-64. PubMed ID: 2647576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.